Germinal Center Lymphocyte Ratios and Successful HIV Vaccines

Paula Gonzalez-Figueroa; Jonathan A Roco; Carola G Vinuesa

doi:10.1016/j.molmed.2016.12.009

Germinal Center Lymphocyte Ratios and Successful HIV Vaccines

Trends Mol Med. 2017 Feb;23(2):95-97. doi: 10.1016/j.molmed.2016.12.009. Epub 2017 Jan 12.

Authors

Paula Gonzalez-Figueroa¹, Jonathan A Roco¹, Carola G Vinuesa²

Affiliations

¹ Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia.
² Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia. Electronic address: [email protected].

PMID: 28089302
DOI: 10.1016/j.molmed.2016.12.009

Abstract

Current HIV vaccines are poor inducers of neutralizing antibodies (nAbs). A recent study in Cell Reports used serial fine-needle aspirates from rhesus macaque lymph nodes following HIV-1 surface envelope glycoprotein (Env) trimer immunization, generating a substantial production of HIV-1 nAbs. A remarkable correlation was found between antibody titers and a high frequency and ratio of germinal center B and T follicular helper (T_FH) lymphocytes.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

AIDS Vaccines / immunology*
AIDS Vaccines / therapeutic use
Animals
Antibodies, Neutralizing / immunology*
Germinal Center / immunology*
Germinal Center / virology
HIV Antibodies / immunology*
HIV Infections / immunology
HIV Infections / prevention & control*
HIV Infections / virology
HIV-1 / immunology*
Humans
Lymphocytes / immunology
Lymphocytes / virology
Macaca mulatta
env Gene Products, Human Immunodeficiency Virus / immunology*
env Gene Products, Human Immunodeficiency Virus / therapeutic use

Substances

AIDS Vaccines
Antibodies, Neutralizing
HIV Antibodies
env Gene Products, Human Immunodeficiency Virus